UK Biobank Ltd
Withdrawal Protocol

UK Biobank Coordinating Centre
1 & 2 Spectrum Way
Adswood
Stockport
Cheshire SK3 0SA

Tel: 0161-475-3951
Fax: 0161-475-5361
E-mail: access@ukbiobank.ac.uk

Document Number: ACCESS_024
Version: 1.0
Issue Date: 03/04/2012

Document Status

<table>
<thead>
<tr>
<th>Draft</th>
<th>Final Draft for Consultation</th>
<th>Signed Off &amp; Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1 Contents

1. Contents........................................................................................................................................... 2
2. Amendment History............................................................................................................................... 2
3. Approvals........................................................................................................................................... 2
3.1 Content........................................................................................................................................... 2
3.2 Quality Review................................................................................................................................. 2
4. Distribution........................................................................................................................................ 3
5. Introduction........................................................................................................................................ 3
6. Purpose and Objectives....................................................................................................................... 3
7. Participants Withdrawal Rights........................................................................................................ 3
8. Impact on Access to the Resource – samples / data not released................................................. 4

2 Amendment History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date Issued</th>
<th>Brief Summary of Change</th>
<th>Owner’s Name/Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>14.12.2011</td>
<td>Original draft</td>
<td>Lorraine Gillions</td>
</tr>
<tr>
<td>0.2</td>
<td>26.03.2012</td>
<td>Final draft for consultation</td>
<td>Jonathan Sellors</td>
</tr>
<tr>
<td>1.0</td>
<td>03.04.2012</td>
<td>Final agreed version</td>
<td>Lorraine Gillions</td>
</tr>
</tbody>
</table>

3 Approvals

3.1 Content

<table>
<thead>
<tr>
<th>Version</th>
<th>Name</th>
<th>Organisation</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>Lorraine Gillions</td>
<td>UK Biobank</td>
<td>Lorraine Gillions</td>
<td>14th December 2011</td>
</tr>
<tr>
<td>0.2</td>
<td>Erin Scobie</td>
<td>UK Biobank</td>
<td>Erin Scobie</td>
<td>15th December 2011</td>
</tr>
<tr>
<td>0.2</td>
<td>Jonathan Sellors</td>
<td>UK Biobank</td>
<td>Jonathan Sellors</td>
<td>26th March 2012</td>
</tr>
<tr>
<td>0.2</td>
<td>Rory Collins</td>
<td>UK Biobank</td>
<td>Rory Collins</td>
<td>30th March 2012</td>
</tr>
</tbody>
</table>

3.2 Quality Review

<table>
<thead>
<tr>
<th>Version</th>
<th>Due Date</th>
<th>Name</th>
<th>Organisation</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4 Distribution

<table>
<thead>
<tr>
<th>Version</th>
<th>Name</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Andrew Trehearne</td>
<td>UK Biobank</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Doc No: ACCESS_024 v1.0 3rd April 2012
4.1 This is a UK Biobank controlled document. The policies described in this document form part of the UK Biobank Access Procedures. Amendments are only permitted via the document change procedure defined in GEN02. On receipt of a new version, please destroy all previous versions (unless a specified earlier version is in use throughout the project).

5 Introduction

5.1 This document has been written to support the Access Procedures and expand upon the Participant Withdrawal process as described in the UK Biobank Protocol, [url to Ethics and Governance Framework] and [url to Participant Information Leaflet].

6 Purpose and Objectives

6.1 This protocol defines the impact of Participant Withdrawal on applications to access the UK Biobank Resource. The objective of this protocol is to ensure that the Access Team and all researchers are aware of their roles and responsibilities’.

7 Participants Withdrawal Rights

7.1 Participants were advised at enrolment that they had the right to withdraw from UK Biobank at any time without having to explain why and without penalty. This was essential to preserve and demonstrate the voluntary nature of participation.

7.2 Despite UK Biobank’s efforts to stay in touch with participants, it may well lose contact with some as they relocate, emigrate, or do not respond to communications. Where a participant has not actively withdrawn, UK Biobank will continue to use the samples and data and maintain linkages, although it will not be able to update some data (e.g. those collected by repeat questionnaire).

7.3 During enrolment, UK Biobank provided information to participants about the options for withdrawal in a Participant Information Leaflet. The 3 options are:
   a. No further contact
   b. No further access
   c. No further use

8 Impact on Access to the Resource – samples not released

8.1 The consequences if a participant withdraws with "no further contact" are as follows:

   8.1.1 Data: (a) UK Biobank can continue to use all the participant's phenotypical data and to link to their health records and (b) from that date, UK Biobank cannot recontact this participant; and

   8.1.2 Samples: UK Biobank can continue to supply these samples to researchers.

8.2 The consequences if a participant withdraws with "no further access" are as follows:

   8.2.1 Data: (a) UK Biobank can continue to use all the participant's phenotypical data and all linkage data supplied to that date and (b) from that date, UK Biobank cannot incorporate any further linkage data relating to that participant and UK Biobank cannot recontact this participant; and

   8.2.2 Samples: UK Biobank can continue to supply these samples to researchers.
8.3 The consequences if a participant withdraws with "no further use" are as follows:

8.3.1 Data: (a) UK Biobank can continue to hold the participant’s phenotypical and linkage data for audit purposes and (b) from that date, UK Biobank cannot incorporate any further linkage data relating to the participant and (c) from that date, UK Biobank cannot continue to supply these data to researchers; and

8.3.2 Samples: (a) UK Biobank cannot continue to supply these samples to researchers and (b) UK Biobank will destroy these samples.

9 Impact on Access to the Resource – samples released

9.1 From UK Biobank’s standpoint the above protocol still applies but the following additional steps are needed (only relevant in relation to the "no further use" option).

9.2 The consequences if a participant withdraws with "no further contact" are as follows:

9.2.1 Data: this would have no impact on the researcher; and

9.2.2 Samples: this would have no impact on the researcher.

9.3 The consequences if a participant withdraws with "no further access" are as follows:

9.3.1 Data: this would have no impact on the researcher; and

9.3.2 Samples: this would have no impact on the researcher.

9.4 The consequences if a participant withdraws with "no further use" are as follows:

9.4.1 Data: UK Biobank contacts the researcher to request that (a) the data (of any type) from that participant are no longer used in further research and effectively deleted (rendered unusable) but that (b) it can still be included in analyses that have already been done; and

9.4.2 Samples: UK Biobank contacts the researcher to request that (a) the samples from that participant are destroyed forthwith and (b) to the extent possible sample remnants should also be destroyed forthwith.